OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Medicine is 176. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-09-01 to 2023-09-01.)

Article	Citations
The proximal origin of SARS-CoV-2	3337
Temporal dynamics in viral shedding and transmissibility of COVID-19	2959
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection	2700
Post-acute COVID-19 syndrome	2436
Antibody responses to SARS-CoV-2 in patients with COVID-19	2211
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections	2095
Extrapulmonary manifestations of COVID-19	1954
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes	1936
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19	1815
Chronic inflammation in the etiology of disease across the life span	1724
A global survey of potential acceptance of a COVID-19 vaccine	1629
An inflammatory cytokine signature predicts COVID-19 severity and survival	1573
Respiratory virus shedding in exhaled breath and efficacy of face masks	1492
A serological assay to detect SARS-CoV-2 seroconversion in humans	1436
Attributes and predictors of long COVID	1291
Age-dependent effects in the transmission and control of COVID-19 epidemics	1188
Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy	1115
A single-cell atlas of the peripheral immune response in patients with severe COVID-19	1098
Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding	1096
Real-time tracking of self-reported symptoms to predict potential COVID-19	1045
Digital technology and COVID-19	866
Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China	858
Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19	805
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma	784
Long-term cardiovascular outcomes of COVID-19	761

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	730
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies	690
A dynamic COVID-19 immune signature includes associations with poor prognosis	661
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19	608
Digital technologies in the public-health response to COVID-19	600
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers	574
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries	563
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	546
Seasonal coronavirus protective immunity is short-lasting	544
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia	538
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease	538
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera	473
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	459
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	454
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation	444
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma	441
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong	437
SARS-CoV-2 infection of the oral cavity and saliva	432
Determinants of COVID-19 disease severity in patients with cancer	431
Single-cell immune landscape of human atherosclerotic plaques	430
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants	422
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration	416
Immune determinants of COVID-19 disease presentation and severity	414
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial	405
Looking beyond COVID-19 vaccine phase 3 trials	402
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma	388
Infection of bat and human intestinal organoids by SARS-CoV-2	387
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein	383
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries	373
Joint international consensus statement for ending stigma of obesity	373
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine	369
Undulating changes in human plasma proteome profiles across the lifespan	367
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda	362
Understanding COVID-19 vaccine hesitancy	361
Long COVID in a prospective cohort of home-isolated patients	360
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals	356
If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future	351
Single-cell multi-omics analysis of the immune response in COVID-19	349
AI in health and medicine	342
Human postprandial responses to food and potential for precision nutrition	342
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR	338
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial	338
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	336
Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks	332
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination	332
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study	331
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19	326
On the responsible use of digital data to tackle the COVID-19 pandemic	323
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus	318
Long COVID after breakthrough SARS-CoV-2 infection	313

Clinical lessons learned from the first leg of the CAR T cell journey	313
Targeting metastatic cancer	312
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy	311
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study	309
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	308
Disease and healthcare burden of COVID-19 in the United States	308
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China	304
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer	303
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity	302
Sixteen novel lineages of SARS-CoV-2 in South Africa	301
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors	297
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa	296
Using human genetics to understand the disease impacts of testosterone in men and women	296
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	293
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease	291
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes	291
Human–computer collaboration for skin cancer recognition	291
Modeling COVID-19 scenarios for the United States	290
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	290
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	289
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	289
Biomarkers for neurodegenerative diseases	287
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension	286
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	285
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers	283
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection	280
Intratumoral heterogeneity in cancer progression and response to immunotherapy	279
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer	275
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant	274
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	271
SARS-CoV-2 variants of concern are emerging in India	271
A deep learning system for differential diagnosis of skin diseases	270
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report	269
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination	267
A rectal cancer organoid platform to study individual responses to chemoradiation	265
Brown adipose tissue is associated with cardiometabolic health	264
Four distinct trajectories of tau deposition identified in Alzheimer’s disease	264
Wearable sensor data and self-reported symptoms for COVID-19 detection	263
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids	262
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination	262
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant	261
Deep learning-based classification of mesothelioma improves prediction of patient outcome	259
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	258
Partial recovery of visual function in a blind patient after optogenetic therapy	257
Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States	256
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters	256
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries	256
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination	254
Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling	249
Deep learning in histopathology: the path to the clinic	248
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells	247
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors	245
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas	243
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	242
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis	239
Combating COVID-19: health equity matters	238
Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle	235
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial	234
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer	234
Regenerative lineages and immune-mediated pruning in lung cancer metastasis	233
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial	233
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial	233
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands	232
Symptoms and risk factors for long COVID in non-hospitalized adults	229
Skin-interfaced biosensors for advanced wireless physiological monitoring in neonatal and pediatric intensive-care units	229
Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers	228
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England	228
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence	227
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin	226
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial	225
Caring for patients with cancer in the COVID-19 era	220
A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research	219
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	218
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom	216
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial	216
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection	216
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease	215
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics	215
Plasma protein patterns as comprehensive indicators of health	214
A stochastic agent-based model of the SARS-CoV-2 epidemic in France	211

A single-cell landscape of high-grade serous ovarian cancer	211
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension	209
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration	209
An immune-cell signature of bacterial sepsis	206
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial	202
Toward personalized treatment approaches for non-small-cell lung cancer	202
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma	201
Targeting the HIF2–VEGF axis in renal cell carcinoma	200
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade	196
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	196
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma	194
Sex differences in cardiometabolic disorders	194
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	193
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist	192
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial	190
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	188
Federated learning for predicting clinical outcomes in patients with COVID-19	186
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma	183
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland	180
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern	180
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies	177
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19	176